Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -67.58% is in line with its 5-year average of -70.12%, around the middle of its 5-year range (-146.10%–-19.21%).
25.72% above its 12-month average of -90.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -15.60%.
RETURN ON ASSETS (ROA)
-67.58%
RETURN ON ASSETS (ROA) AVG TTM
-90.98%
RETURN ON ASSETS (ROA) AVG 3Y
-83.38%
RETURN ON ASSETS (ROA) AVG 5Y
-70.12%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+25.72%
CURRENT VS 3Y AVG
+18.95%
CURRENT VS 5Y AVG
+3.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-25.17%
median of 451 covered companies
CURRENT VS SECTOR MEDIAN
-168.49%
vs the sector median at left
Bionano Genomics, Inc.
Market Cap
$16.58M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$16.54M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$16.22M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$15.91M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$15.30M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$18.77M
Return on Assets (ROA)
-548.74%
TTM Avg
-346.44%
3Y Avg
-242.08%
5Y Avg
-167.09%
Market Cap
$18.82M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$14.28M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$13.62M
Return on Assets (ROA)
-85.85%
TTM Avg
-102.78%
3Y Avg
-95.22%
5Y Avg
-76.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bionano Genomics, Inc. (BNGO) | $16.58M | -67.58% | -90.98% | -83.38% | -70.12% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -116.60% | -66.28% | -71.56% | -63.10% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -154.34% | -227.23% | -240.86% | -184.63% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -38.41% | -84.87% | -95.12% | -75.66% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -213.77% | -110.51% | -93.41% | -68.22% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | -548.74% | -346.44% | -242.08% | -167.09% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -39.68% | -29.52% | -26.86% | -20.28% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -32.53% | -31.07% | -30.77% | -29.89% |
| IN8bio, Inc. (INAB)vs › | $13.62M | -85.85% | -102.78% | -95.22% | -76.09% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -123.23% | -153.35% | -205.77% | -166.29% |
ROA
-67.6%
ROE
-101.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -35.87% |
| 2024-12-31 | -146.10% |
| 2023-12-31 | -108.44% |
| 2022-12-31 | -43.12% |
| 2021-12-31 | -19.21% |
| 2020-12-31 | -68.00% |
| 2019-12-31 | -98.70% |
| 2018-12-31 | -74.57% |
| 2017-12-31 | -230.31% |
| 2016-12-31 | -127.46% |
